Tegelased 3

European multicenter network to evaluate pharmacokinetics, safety and efficacy of Meropenem in neonatal sepsis and meningitis

Description:

NeoMero1
: An open label, randomised, multicenter, comparator-controlled study to evaluate the PK, efficacy and safety of meropenem as compared with standard antibiotic therapy in neonates and infants aged < 3 months treated in neonatal intensive care units (NICU) for late onset sepsis (LOS) defined as sepsis appearing after 72 hrs from birth;

NeoMero2: An open label, multicenter, observational study to evaluate the PK and safety of meropenem in neonates and infants aged < 3 months with bacterial meningitis admitted to NICUs.

Funding: European Commission, under the FP7 programme

EUDRA-CT: 2011-001515-31

Link: https://cordis.europa.eu/project/rcn/93635/reporting/en

Partners:
  • University of Tartu, Estonia; 
  • INSERM SC10-US19, France; 
  • Azienda Ospedaliera-University of Padua, Padua-Italy; 
  • Bambino Gesù Children’s Hospital, IRCCS, Rome Italy; 
  • University Department of Paediatrics, Italy; 
  • Neonatoloji Kliniği, Turkey;
  • Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Italy; 
  • Tallinn Children’s Hospital, Estonia; 
  • St George's University of London, UK; 
  • Aristotle University School of Health Sciences, Hippokration Hospital, Greece; 
  • Tartu University Hospital, Estonia;
  • Aristotle University School of Health Sciences, Papageorgiou Hospital, Greece; 
  • Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Italy; 
  • Hospital Universitario Infantil LA PAZ- H. Carlos III; Vilnius University,Lithuania; 
  • University of Aberdeen, UK; 
  • University of Padova, Italy


Project's status: Finished



Tegelased 3
ENG